Yu, Y., Zhou, J., Yuan, Y., Zhuo, M., Shi, J., Pan, Y., Shen, L., Fu, S., Spira, A., Wu, L., Lv, D., Yang, B., Zheng, J., Fang, X., Song, B., Ma, S., Li, J., Zhong, B., Zhang, T., Lu, S. (2026). A phase 1/2 study of TSN1611, a highly selective oral KRAS G12D inhibitor, in solid tumors: Efficacy and safety in KRAS G12D–mutated NSCLC patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8516